RBM45

Across TCGA pan-cancer cohorts, RBM45 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBM45 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBM45 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RBM45 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where RBM45 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.731	0.929	.008	48	view →
CCRCC	DFS	Median	II,III,IV	0.770	0.966	.002	16	view →
LSCC	DFS	Tertile	All	0.840	0.575	.009	14	view →
GBM	DFS	Quartile	All	0.928	0.627	.011	10	view →
PDAC	OS	Median	III,IV	1.000	0.537	.008	10	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RBM45–HNSC (OS)

Open the HNSC breakdown →